ITCI submits Supplemental New Drug Applications (sNDAs) for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults.
2/22/2021
Cibus, a leader in precision gene editing in agriculture, today announced that its first field trials have confirmed greenhouse results of a non-GMO trait that provides tolerance to white mold (Sclerotinia). This milestone represents a major step in Cibus’ mission to breed a durable resistant plant with its Rapid Trait Development System (RTDSTM), as well as a breakthrough for a complex challenge that GMO and traditional technologies have been unable to fully address. This trait is among Cibus’ 14 trait products that the US Department of Agriculture, under its “Am I Regulated” process, has recently ruled were not subject to regulation under 7 CFR Part 340 and instead are regulated in the same manner as traits developed using conventional breeding practices.
1/12/2021
Genome editing techniques that modify the DNA of plants do not pose more hazards than conventional breeding or techniques that introduce new DNA into a plant, an EFSA assessment concludes.
11/24/2020
Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).
11/10/2020
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com. This reflects the broadening of the firm's strategic direction since launching its 3rd fund in 2017 to reflect its focus on transformational science and technology in healthcare.
10/2/2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the presentation of an on-demand e-poster titled “First-in-Human Study of Camidanlumab Tesirine (ADCT-301, Cami), an anti-CD25 Targeted Therapy in Patients with Advanced...
9/17/2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that preclinical data related to camidanlumab tesirine (Cami, formerly ADCT-301) has been published in the Journal for ImmunoTherapy of Cancer, the online ...
9/10/2020
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.
9/9/2020
Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”):
9/2/2020
Royalty Pharma (Nasdaq: RPRX) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that Biohaven has secured up to $250 million in funding to advance the company’s CGRP receptor antagonist program through the development of zavegepant (formerly known as vazegepant).
8/7/2020
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
7/17/2020
ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).
7/6/2020
New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:ADCT). The company raised $267.6 million through the sale of 14,082,475 of its common shares priced at $19.00 per share.
6/30/2020
New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX).
6/25/2020
Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at a price to the public of $28.00 per share.
6/15/2020
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that interim clinical data on loncastuximab tesirine (Lonca, formerly ADCT-402) will be presented in an oral presentation and e-Poster at the virtual 25th Congress of the European Hematology Association (EHA25).
5/21/2020
ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today the closing of its initial public offering of 14,082,475 shares of its common shares at a price of $19.00 per ...
5/19/2020
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has launched the initial public offering of 7,355,000 shares of its common shares. In addition, ADC Therapeutics has granted the underwriters an option to purchase up to 1,103,250 additional common shares. The initial public offering price is expected to be between $16.00 and $18.00 per common share. The common shares have been approved for listing on the New York Stock Exchange under the ticker symbol “ADCT.”
5/11/2020
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced that it entered into a $115 million Convertible Credit Facility (the “Convertible Credit Facility”) with funds affiliated with Deerfield Management Company, L.P. (collectively, “Deerfield”).
5/1/2020
Enterin, Inc., a clinical-stage company focused on neurodegenerative diseases, announced today that it has received feedback from the FDA laying out the path for a Phase 1/2a study in hospitalized patients with COVID-19 infection. The study will involve 10 U.S. sites and will enroll 80 hospitalized patients. Patients will have been diagnosed with SARS-CoV-2, have an SpO2 ...
4/20/2020
